1 |
Brown, M. S., and J. L. Goldstein(1986), 'A receptor-mediated pathway for cholesterol homeostasis,' Science, 232(4746), 34-47
DOI
|
2 |
Strutt et al, 2004 Guidelines for Hyperlipidemia Therapy, 2006
|
3 |
Blasetto, J. W., E. A. Stein, W. V. Brown, R. Chitra, and A. Raza (2003), 'Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups,' Am J Cardiol, 91(5A), 3C-10C; discussion10C
DOI
ScienceOn
|
4 |
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001), "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)," Jama, 285(19), 2486-2497
DOI
ScienceOn
|
5 |
Sechtem, S. Silber, T. Thomsen, and D. Wood(2003), "European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice," Eur Heart J, 24(17), 1601-1610
|
6 |
Endo, A., Y. Tsujita, M. Kuroda, and K. Tanzawa(1977), 'Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3- hydroxy-3-methylglutaryl-coenzyme A reductase,' Eur J Biochem, 77(1), 31-36
DOI
ScienceOn
|
7 |
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.(1998) 'Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.' N Engl J Med, 339, 1349-1357
DOI
ScienceOn
|
8 |
Lloret, R., J. Ycas, M. Stein, and S. Haffner(2006), 'Comparison of rosuvastatin versus atorvastatin in Hispanic- Americans with hypercholesterolemia(from the STARSHIP trial),' Am J Cardiol, 98(6), 768-773
DOI
ScienceOn
|
9 |
Carrilho, A. J., W. L. Medina, E. R. Nakandakare, and E. C. Quintao(1997), 'Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine,' Clin Pharmacol Ther, 62(1), 82-88
DOI
|
10 |
Davidson, M., P. Ma, E. A. Stein, A. M. Gotto, Jr., A. Raza, R. Chitra, and H. Hutchinson(2002), 'Comparison of effects on low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia,' Am J Cardiol, 89 (3), 268-275
DOI
ScienceOn
|
11 |
De Backer, G., E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V. Manger Cats, K. Orth- Gomer, J. Perk, K. Pyorala, J. L. Rodicio, S. Sans, V. Sansoy, U. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (2001), 'Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III),' Jama, 285(19), 2486-2497
DOI
ScienceOn
|
12 |
Jones, P., S. Kafonek, I. Laurora, and D. Hunninghake( 1998), 'Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatinin patients with hypercholesterolemia(the CURVES study),' Am J Cardiol, 81 (5), 582-587
DOI
ScienceOn
|
13 |
Gagne, C. H. E. Bays, S. R. Weiss, P. Mata, K. Quinto, M. Melino, M. Cho, T. A. Musliner, and B. Gumbiner(2002), 'Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia,' Am J Cardiol, 90(10), 1084-1091
DOI
ScienceOn
|
14 |
Heart Protection Study Collaborative Group (2002), 'MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial,' Lancet, 360(9326), 7-22
DOI
ScienceOn
|
15 |
Japan Atherosclerosis Society (2002), 'Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular disease.' Tokyo JAS
|
16 |
Menotti, A., A. Keys, H. Blackburn, D. Kromhout, M. Karvonen, A. Nissinen, J. Pekkanen, S. Punsar, F. Fidanza, S. Giampaoli, F. Seccareccia, R. Buzina, I. Mohacek, S. Nedeljkovic, C. Aravanis, A. Dontas, H. Toshima, and M. Lanti(1996), 'Comparison of multivariate predictive power of major risk factors for coronary heart diseases in different countries: results from eight nations of the Seven Countries Study, 25-year follow-up,' J Cardiovasc Risk, 3(1), 69-75
DOI
|
17 |
Olsson, A. G., H. Istad, O. Luurila, L. Ose, S. Stender, J. Tuomilehto, O. Wiklund, H. Southworth, J. Pears, and J. W. Wilpshaar(2002), 'Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia,' Am Heart J, 144(6), 1044-1051
DOI
ScienceOn
|
18 |
Stein E, Strutt KL, Miller E, Southworth H. (2001) 'Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia' Atherosclerosis (2) 90
|
19 |
Sacks, F. M., L. A. Moye, B. R. Davis, T. G. Cole, J. L. Rouleau, D. T. Nash, M. A. Pfeffer, and E. Braunwald(1998), 'Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial,' Circulation, 97(15), 1446-1452
DOI
ScienceOn
|
20 |
Stamler, J., D. Wentworth, and J. D. Neaton(1986), 'Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT),' Jama, 256(20), 2823-2828
DOI
ScienceOn
|
21 |
Strutt, K. R. Caplan, H. Hutchison, A. Dane, and J. Blasetto (2004), 'More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy,' Circ J, 68(2), 107- 113
DOI
ScienceOn
|
22 |
Mabuchi, H., T. Kita, M. Matsuzaki, Y. Matsuzawa, N. Nakaya, S. Oikawa, Y. Saito, J. Sasaki, K. Shimamoto, and H. Itakura (2002), 'Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT),' Circ J, 66(12), 1096-1100
DOI
ScienceOn
|
23 |
Maron, D. J., S. Fazio, and M. F. Linton(2000), 'Current perspectives on statins,' Circulation, 101(2), 207-213
DOI
ScienceOn
|
24 |
Ulahannan, T. J.(1998), 'Amiodarone prophylaxis for atrial fibrillation after cardiac surgery,' N Engl J Med, 338(19), 1384
|
25 |
Scandinavian Simvastatin Survival Study Group (1994), 'Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),' Lancet, 344(8934), 1383-1389
|
26 |
Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and C. J. Packard(1995), 'Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group,' N Engl J Med, 333(20), 1301-1307
DOI
ScienceOn
|
27 |
Sytkowski, P. A., R. B. D'Agostino, A. Belanger, and W. B. Kannel(1996), 'Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989,' Am J Epidemiol, 143(4), 338-350
DOI
ScienceOn
|